iBio, Inc. Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Year	2023	2022	2021	2020	2019	2018 - 2009
Net Income	-65.01	-50.39	-23.47	-38.26	-17.85	Upgrade
Depreciation & Amortization	1.38	3.79	2.41	2.24	1.75	Upgrade
Share-Based Compensation	4.39	4.38	1.59	0.39	0.24	Upgrade
Other Operating Activities	28.8	4.74	-10.86	0.47	1.63	Upgrade
Operating Cash Flow	-30.44	-37.48	-30.06	-13.35	-13.98	Upgrade
Capital Expenditures	-3.14	-11.63	-5.16	-1.15	-0.99	Upgrade
Acquisitions	-0.69	0	0	0	0	Upgrade
Change in Investments	10.84	6.5	-19.82	0	0	Upgrade
Other Investing Activities	-	-	-1.5	-	-	Upgrade
Investing Cash Flow	7.01	-5.13	-26.48	-1.15	-0.99	Upgrade
Share Issuance / Repurchase	11.45	0.08	83.88	68.82	3.81	Upgrade
Debt Issued / Paid	-9.15	-6.15	-0.33	-1.46	-0.2	Upgrade
Other Financing Activities	-	-0.05	-4.71	-2.17	-0.16	Upgrade
Financing Cash Flow	2.3	-6.13	78.84	65.19	3.45	Upgrade
Exchange Rate Effect	0.03	0	-0	-0	-0	Upgrade
Net Cash Flow	-21.09	-48.73	22.29	50.69	-11.51	Upgrade
Free Cash Flow	-33.57	-49.11	-35.23	-14.5	-14.97	Upgrade
Free Cash Flow Margin	-	-2606.69%	-1485.70%	-885.16%	-741.58%	Upgrade
Free Cash Flow Per Share	-54.84	-112.63	-90.03	-115.45	-395.36	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).